The surface charge of liposomal adjuvants is decisive for their interactions with the Calu-3 and A549 airway epithelial cell culture models

European Journal of Pharmaceutics and Biopharmaceutics

Volumn 87, Issue 3, 2014, Pages 480-488

  Ingvarsson, Pall Thor ^a,d   Rasmussen, Ida Svahn ^a   Viaene, Michelle ^a,b   Irlik, Przemyslaw Jedrzej ^a,c   Nielsen, Hanne Mørck ^a   Foged, Camilla ^a  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

^b GHENT UNIVERSITY   (Belgium)

^c UNIVERSITY OF COPENHAGEN   (Denmark)

^d STATENS SERUM INSTITUT   (Denmark)

Author keywords

A549; Calu 3; In vitro; Liposomes; Mucosal adjuvant; Pulmonary administration; Vaccine

Indexed keywords

AMPHOLYTE; DIMETHYLDIOCTADECYLAMMONIUM BROMIDE; DISTEAROYLPHOSPHATIDYLCHOLINE; LIPOSOME; OVALBUMIN; TREHALOSE; TREHALOSE 6,6' DIBEHENATE; UNCLASSIFIED DRUG; 1,2-DISTEAROYLLECITHIN; CATION; DIMETHYLDIOCTADECYLAMMONIUM; GLYCOLIPID; IMMUNOLOGICAL ADJUVANT; LIPID; PHARMACEUTICAL VEHICLES AND ADDITIVES; PHOSPHATIDYLCHOLINE; QUATERNARY AMMONIUM DERIVATIVE; TREHALOSE 6,6'-DIBEHENATE; VACCINE;

ARTICLE; CELL VIABILITY; CHEMICAL INTERACTION; CONFOCAL MICROSCOPY; CONTROLLED STUDY; DIFFUSION; EPITHELIUM CELL; LIPOSOMAL DELIVERY; MUCUS SECRETION; PHASE TRANSITION; RESPIRATORY EPITHELIUM; SURFACE CHARGE; ULTRASOUND; ZETA POTENTIAL; CELL SURVIVAL; DRUG EFFECTS; HUMAN; IMMUNOLOGY; ISOLATION AND PURIFICATION; LUNG; MUCUS; RESPIRATORY TRACT MUCOSA; TUMOR CELL LINE;

ADJUVANTS, IMMUNOLOGIC; ADJUVANTS, PHARMACEUTIC; CATIONS; CELL LINE, TUMOR; CELL SURVIVAL; EPITHELIAL CELLS; GLYCOLIPIDS; HUMANS; LIPIDS; LIPOSOMES; LUNG; MUCUS; OVALBUMIN; PHOSPHATIDYLCHOLINES; QUATERNARY AMMONIUM COMPOUNDS; RESPIRATORY MUCOSA; VACCINES;

EID: 84904251152     PISSN: 09396411     EISSN: 18733441     Source Type: Journal    
DOI: 10.1016/j.ejpb.2014.04.001     Document Type: Article

References (38)

1. M.R. Neutra, and P.A. Kozlowski Mucosal vaccines: the promise and the challenge Nat. Rev. Immunol. 6 2006 148 158
2. O. Borges, F. Lebre, D. Bento, G. Borchard, and H.E. Junginger Mucosal vaccines: recent progress in understanding the natural barriers Pharm. Res. 27 2010 211 223
3. J.P. Amorij, V. Saluja, A.H. Petersen, W.L.J. Hinrichs, A. Huckriede, and H.W. Frijlink Pulmonary delivery of an insulin-stabilized influenza subunit vaccine prepared by spray-freeze drying induces systemic, mucosal humoral as well as cell-mediated immune responses in BALB/c mice Vaccine 25 2007 8707 8717
4. A. Vujanic, K.J. Snibson, J.L.K. Wee, S.J. Edwards, M.J. Pearse, J.P.Y. Scheerlinck, and P. Sutton Long-term antibody and immune memory response induced by pulmonary delivery of the influenza Iscomatrix vaccine Clin. Vaccine Immunol. 19 2012 79 83
5. A. Vujanic, J.L.K. Wee, K.J. Snibson, S. Edwards, M. Pearse, C. Quinn, M. Moloney, S. Taylor, J.P.Y. Scheerlinck, and P. Sutton Combined mucosal and systemic immunity following pulmonary delivery of ISCOMATRIX (TM) adjuvanted recombinant antigens Vaccine 28 2010 2593 2597
6. P. Nordly, H.B. Madsen, H.M. Nielsen, and C. Foged Status and future prospects of lipid-based particulate delivery systems as vaccine adjuvants and their combination with immunostimulators Expert Opin. Drug Deliv. 6 2009 657 672
7. D.T. O'Hagan, and E. De Gregorio The path to a successful vaccine adjuvant - 'The long and winding road' Drug Discov. Today 14 2009 541 551
8. B. Guy The perfect mix: recent progress in adjuvant research Nat. Rev. Microbiol. 5 2007 505 517
9. J.P. Amorij, G.F.A. Kersten, V. Saluja, W.F. Tonnis, W.L.J. Hinrichs, B. Slütter, S.M. Bal, J.A. Bouwstra, A. Huckriede, and W. Jiskoot Towards tailored vaccine delivery: needs, challenges and perspectives J. Control. Release 161 2012 363 376
10. K. Chen, and A. Cerutti Vaccination strategies to promote mucosal antibody responses Immunity 33 2010 479 491
11. W.M. Foster, E. Langenback, and E.H. Bergofsky Measurement of tracheal and bronchial mucus velocities in man: relation to lung clearance J. Appl. Physiol. 48 1980 965 971
12. L.P. Nicod Lung defences: an overview Eur. Respir. Rev. 14 2005 45 50
13. J.V. Fahy, and B.F. Dickey Airway mucus function and dysfunction N. Engl. J. Med. 363 2010 2233 2247
14. R.A. Cone Barrier properties of mucus Adv. Drug Deliv. Rev. 61 2009 75 85
15. J. Davidsen, I. Rosenkrands, D. Christensen, A. Vangala, D. Kirby, Y. Perrie, E.M. Agger, and P. Andersen Characterization of cationic liposomes based on dimethyldioctadecylammonium and synthetic cord factor from M. tuberculosis (trehalose 6,6′-dibehenate) - a novel adjuvant inducing both strong CMI and antibody responses Biochim. Biophys. Acta Biomembr. 1718 2005 22 31
16. E.M. Agger, I. Rosenkrands, J. Hansen, K. Brahimi, B.S. Vandahl, C. Aagaard, K. Werninghaus, C. Kirschning, R. Lang, and D. Christensen Cationic liposomes formulated with synthetic mycobacterial cordfactor (CAF01): a versatile adjuvant for vaccines with different immunological requirements PLoS One 3 2008 e3116
17. A. Joseph, N. Itskovitz-Cooper, S. Samira, O. Flasterstein, H. Eliyahu, D. Simberg, I. Goldwaser, Y. Barenholz, and E. Kedar A new intranasal influenza vaccine based on a novel polycationic lipid - ceramide carbamoyl-spermine (CCS): I. Immunogenicity and efficacy studies in mice Vaccine 24 2006 3990 4006
18. R.S. Rosada, L.G. Torre, F.G. Frantz, A.P.F. Trombone, C.R. Zárate-Bladés, D.M. Fonseca, P.R.M. Souza, I.T. Brandão, A.P. Masson, É.G. Soares, S.G. Ramos, L.H. Faccioli, C.L. Silva, M.H.A. Santana, and A.A.M. Coelho-Castelo Protection against tuberculosis by a single intranasal administration of DNA-hsp65 vaccine complexed with cationic liposomes BMC Immunol. 9 2008 38
19. M.E. Baca-Estrada, M. Foldvari, and M. Snider Induction of mucosal immune responses by administration of liposome-antigen formulations and interleukin-12 J. Interferon Cytokine Res. 19 1999 455 462
20. D. Christensen, C. Foged, I. Rosenkrands, C.V. Lundberg, P. Andersen, E.M. Agger, and H.M. Nielsen CAF01 liposomes as a mucosal vaccine adjuvant: in vitro and in vivo investigations Int. J. Pharm. 390 2009 19 24
21. M. Sakagami In vivo, in vitro and ex vivo models to assess pulmonary absorption and disposition of inhaled therapeutics for systemic delivery Adv. Drug Deliv. Rev. 58 2006 1030 1060
22. F.L. Jahnsen, D.H. Strickland, J.A. Thomas, I.T. Tobagus, S. Napoli, G.R. Zosky, D.J. Turner, P.D. Sly, P.A. Stumbles, and P.G. Holt Accelerated antigen sampling and transport by airway mucosal dendritic cells following inhalation of a bacterial stimulus J. Immunol. 177 2006 5861 5867
23. F. Blank, B. Rothen-Rutishauser, and P. Gehr Dendritic cells and macrophages form a transepithelial network against foreign particulate antigens Am. J. Respir. Cell Mol. Biol. 36 2007 669 677
24. C. Kitson, B. Angel, D. Judd, S. Rothery, N.J. Severs, A. Dewar, L. Huang, S.C. Wadsworth, S.H. Cheng, and D.M. Geddes The extra-and intracellular barriers to lipid and adenovirus-mediated pulmonary gene transfer in native sheep airway epithelium Gene Ther. 6 1999 534 546
25. N.N. Sanders, E. Van Rompaey, S.C. De Smedt, and J. Demeester On the transport of lipoplexes through cystic fibrosis sputum Pharm. Res. 19 2002 451 456
26. L.M. Ensign, C. Schneider, J.S. Suk, R. Cone, and J. Hanes Mucus penetrating nanoparticles: biophysical tool and method of drug and gene delivery Adv. Mater. 24 2012 3887 3894
27. A. Henning, M. Schneider, M. Bur, F. Blank, P. Gehr, and C.-M. Lehr Embryonic chicken trachea as a new in vitro model for the investigation of mucociliary particle clearance in the airways AAPS PharmSciTech 9 2008 521 527
28. M. Hamborg, L. Jorgensen, A.R. Bojsen, D. Christensen, and C. Foged Protein antigen adsorption to the DDA/TDB liposomal adjuvant: effect on protein structure, stability, and liposome physicochemical characteristics Pharm. Res. 30 2012 140 155
29. M. Hamborg, Physical Stability of Subunit Vaccines: Interactions between Liposomal Adjuvants and Protein Antigens, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, 2013.
30. M. Henriksen-Lacey, D. Christensen, V.W. Bramwell, T. Lindenstrøm, E.M. Agger, P. Andersen, and Y. Perrie Liposomal cationic charge and antigen adsorption are important properties for the efficient deposition of antigen at the injection site and ability of the vaccine to induce a CMI response J. Control. Release 145 2010 102 108
31. J. Geys, B. Nemery, and P. Hoet Optimisation of culture conditions to develop an in vitro pulmonary permeability model Toxicol. In Vitro 21 2007 1215 1219
32. R. Tréhin, U. Krauss, A.G. Beck-Sickinger, H.P. Merkle, and H.M. Nielsen Cellular uptake but low permeation of human calcitonin-derived cell penetrating peptides and Tat (47-57) through well-differentiated epithelial models Pharm. Res. 21 2004 1248 1256
33. S. Dokka, D. Toledo, X. Shi, V. Castranova, and Y. Rojanasakul Oxygen radical-mediated pulmonary toxicity induced by some cationic liposomes Pharm. Res. 17 2000 521 525
34. R.K. Scheule, J.A.S. George, R.G. Bagley, J. Marshall, J.M. Kaplan, G.Y. Akita, K.X. Wang, E.R. Lee, D.J. Harris, C. Jiang, N.S. Yew, A.E. Smith, and S.H. Cheng Basis of pulmonary toxicity associated with cationic lipid-mediated gene transfer to the mammalian lung Hum. Gene Ther. 8 1997 689 707
35. C. Klinguer, A. Beck, P. De-Lys, M.C. Bussat, A. Blaecke, F. Derouet, J.Y. Bonnefoy, T.N. Nguyen, N. Corvaïa, and D. Velin Lipophilic quaternary ammonium salt acts as a mucosal adjuvant when co-administered by the nasal route with vaccine antigens Vaccine 19 2001 4236 4244
36. H.U. Eirheim, C. Bundgaard, and H.M. Nielsen Evaluation of different toxicity assays applied to proliferating cells and to stratified epithelium in relation to permeability enhancement with glycocholate Toxicol. In Vitro 18 2004 649 657
37. B.D. Freimark, H.P. Blezinger, V.J. Florack, J.L. Nordstrom, S.D. Long, D.S. Deshpande, S. Nochumson, and K.L. Petrak Cationic lipids enhance cytokine and cell influx levels in the lung following administration of plasmid: cationic lipid complexes J. Immunol. 160 1998 4580 4586
38. T. Sou, E.N. Meeusen, M. de Veer, D.A.V. Morton, L.M. Kaminskas, and M.P. McIntosh New developments in dry powder pulmonary vaccine delivery Trends Biotechnol. 29 2011 191 198